Equity Considerations in COVID‐19 Vaccination Studies of Individuals With Autoimmune Inflammatory Rheumatic Diseases
Authors' conclusion
Sex and age were the most frequently considered PROGRESS-Plus factors in studies of COVID-19 vaccination in individuals with AIRDs. The generalizability of evidence to populations experiencing inequities is uncertain.
Study context
- Population
- Studies of COVID-19 vaccination in individuals with autoimmune inflammatory rheumatic diseases (AIRDs)all cohort studies
- Participants
- 19 studies
- Outcome
- Extent to which populations experiencing inequities were considered (PROGRESS-Plus factors)
Methodological detailsPROGRESS-Plus framework
- PROGRESS-Plus framework
Pooled result
As reported in the abstract
Equity considerations (PROGRESS-Plus factors)
- Described differences in baseline COVID-19 risk across age
- 3 studies (16%)
- Eligibility criteria based on occupation and age
- 2 studies (11%)
- Described participant age and sex
- 19 studies
- Controlled for age and/or sex as confounders
- 12 studies (67%)
- Subgroup analyses across ≥1 PROGRESS-Plus factor, most commonly age
- 8 studies (47%)
- Interpreted applicability for ≥1 PROGRESS-Plus factor
- 10 studies (53%)
- Applicability interpreted by age
- 47%
- Applicability interpreted by ethnicity
- 16%
- Applicability interpreted by sex
- 16%
- Applicability interpreted by multimorbidity
- 11%
Original publication
Equity Considerations in COVID‐19 Vaccination Studies of Individuals With Autoimmune Inflammatory Rheumatic Diseases. Arthritis Care Res (Hoboken). Published 7 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →